Tissue-resident memory T cells in immune-related adverse events: friend or foe?
Many cancer patients experience toxicity during checkpoint blockade immunotherapy, which often leads to treatment discontinuation. To this end, understanding the mechanisms mediating immune-related adverse events (irAE) should ultimately enable improvement in clinical outcomes. Recent work has revea...
Saved in:
Main Authors: | Robin Reschke, Thomas F Gajewski |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2023-12-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2023.2197358 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Endocrine Adverse Events in Patients Treated with Immune Checkpoint Inhibitors: A Comprehensive Analysis
by: Meriç Dökmetaş, et al.
Published: (2025-01-01) -
The impact of immune-related adverse events on the outcome of advanced gastric cancer patients with immune checkpoint inhibitor treatment
by: Tianhang Zhang, et al.
Published: (2024-12-01) -
CD73/adenosine dynamics in treatment-induced pneumonitis: balancing efficacy with risks of adverse events in combined radio-immunotherapies
by: Lena Gockeln, et al.
Published: (2025-01-01) -
Immune-related adverse events with renal colic as the main manifestation: a case report of sintilimab-induced ureteritis/cystitis treated by ureteral stent and review of the literature
by: Jiaxiang Ji, et al.
Published: (2024-12-01) -
Pembrolizumab Induced Recall Dermatitis Occurring 5 Years After Radiotherapy
by: Caroline J. Cushman, et al.
Published: (2024-11-01)